ImmunoCellular Financial Statements From 2010 to 2024
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
Check ImmunoCellular Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunoCellular main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . ImmunoCellular financial statements analysis is a perfect complement when working with ImmunoCellular Therapeutics Valuation or Volatility modules.
ImmunoCellular |
ImmunoCellular Therapeutics Company Current Valuation Analysis
ImmunoCellular Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ImmunoCellular Therapeutics Current Valuation | (1.69 M) |
Most of ImmunoCellular Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoCellular Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, ImmunoCellular Therapeutics has a Current Valuation of (1.69 Million). This is 100.01% lower than that of the Biotechnology sector and 100.04% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.01% higher than that of the company.
ImmunoCellular Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImmunoCellular Therapeutics's current stock value. Our valuation model uses many indicators to compare ImmunoCellular Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImmunoCellular Therapeutics competition to find correlations between indicators driving ImmunoCellular Therapeutics's intrinsic value. More Info.ImmunoCellular Therapeutics is rated fifth overall in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value ImmunoCellular Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ImmunoCellular Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmunoCellular Therapeutics' earnings, one of the primary drivers of an investment's value.About ImmunoCellular Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ImmunoCellular Therapeutics income statement, its balance sheet, and the statement of cash flows. ImmunoCellular Therapeutics investors use historical funamental indicators, such as ImmunoCellular Therapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although ImmunoCellular Therapeutics investors may use each financial statement separately, they are all related. The changes in ImmunoCellular Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ImmunoCellular Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ImmunoCellular Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ImmunoCellular Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ImmunoCellular Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ImmunoCellular Therapeutics' short interest history, or implied volatility extrapolated from ImmunoCellular Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |